Close Menu

Cancer Genetics

The firm said in an SEC document that it may from time to time offer common stock, preferred stock, warrants, and overallotment purchase rights and units. 

The firm’s biopharma revenues increased 11 percent, while clinical service revenues grew 20 percent, and discovery service revenue increased 12 percent.

Its CEO said the firm has a clear path to achieving profitability, and that a big-data and artificial intelligence initiative will further expand its margins.

There was a lot of growth in the precision medicine field in the past year, and some experts believe the FDA's decision to hold off on regulating LDTs could spur more innovation.

The moves are part of an effort to consolidate and reduce costs related to administrative, finance, and operational support functions.

The firm saw a 204 percent increase in clinical services test volume year over year driven by increased offerings in several testing services.

The companies will work together to advance the use of ApoCell's rare cell isolation platform for cancer molecular profiling and monitoring in clinical trials.

The recent failure of Bristol-Myers Squibb's lung cancer immunotherapy to meet its primary endpoint demonstrates the challenge of working with imperfect biomarkers.

The company said it plans to use the proceeds of the offering for general corporate purposes.

Pages